---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-333912"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2026-08-05T12:05:10+00:00"
generated_at: "2026-08-05T12:10:10.702735+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ImageneBio Q2 2026 net loss $10.2M ($0.63/sh); cash $136.2M funds into Q1 2028

## Summary
- Net loss of $10.2M ($0.63 loss per share) vs $10.7M ($4.46) in Q2 2025.
- Cash, equivalents and marketable securities $136.2M as of June 30, 2026.
- R&D expenses $6.7M (up from $5.7M); G&A expenses $5.1M (up from $1.7M) YoY.
- Phase 2b ADAPTIVE trial for olevaprubart in atopic dermatitis on track; topline data expected Q4 2027.
- Appointed Yanina Grant-Huerta as CFO and Matt Robbins as General Counsel in July 2026.

## SEC filing metadata
- accession: 0001193125-26-333912
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2026-08-05T12:05:10+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312526333912/0001193125-26-333912-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312526333912/d166048d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-333912
- JSON: https://secwatch.observer/filing/0001193125-26-333912.json
- Plain text: https://secwatch.observer/filing/0001193125-26-333912.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.